Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
PF-08046037 joins PF-08046054 in clinical development.
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
RPCAR01 starts a phase 1 study, albeit one sponsored by academics.
Emilta-L continues to show worse efficacy than a rival ADC discontinued by Pfizer.
Early data with ELVN-001 hold up well against olverembatinib and TERN-701.
